Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conjugated estrogens ANDA watched by Capitol Hill: two Ohio Republicans meet with FDA.

Executive Summary

DURAMED CONJUGATED ESTROGENS ANDA BRIEFING FOR TWO OHIO REPUBLICAN CONGRESSMEN was conducted on Oct. 3 by a group of senior FDA officials. Deputy Commissioner for External Affairs Sharon Smith Holston and Center for Drug Evaluation & Research Director Janet Woodcock, MD, met with Sen. DeWine (R-Ohio) and Rep. Portman (R-Ohio) to discuss the concerns of the Cincinnati, Ohio-based company, which has had an ANDA pending at FDA since September 1994 for a generic version of Wyeth-Ayerst's Premarin. Portman represents the 2nd congressional district in Ohio, including Cincinnati.
UsernamePublicRestriction

Register

PS029027

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel